General Information of DFM (ID: F16554)
Name
Pantoprazole 40 mg tablet
Company
Mylan Pharamceuticals
Active Pharmaceutical Ingredient (API) Pantoprazole API Info click to show the detail info of this API
Gastro-oesophageal reflux disease ICD-11: DA22 Approved
Drug Inactive Ingredient (DIGs)
DIG ID DIG Info DIG Name DIG Functional Class
E0F2PK DIG Info Calcium stearate lubricant
E0DB2E DIG Info Carbonic acid disodium salt Alkalizing agent ...
E0M0IE DIG Info Ferric hydroxide oxide yellow Colorant
E02FBG DIG Info Ferrosoferric oxide Colorant
E0Q6DQ DIG Info Mannitol Diluent ...
E0M1JK DIG Info Propylene glycol Antimicrobial preservative ...
E05BSD DIG Info Titanium dioxide Coating agent ...
E0K0OU DIG Info Triethyl citrate Plasticizing agent ...
Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM
      Oxidoreductase (ORase)
            DBT Name: Albendazole monooxygenase (CYP3A4) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Interacting DIG Propylene glycol
                    Biological Activity Inhibition ratio < 20 % (tested by experiment) [1]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP3A4_HUMAN
      Transmembrane channel/porin (TC/P)
            DBT Name: Glycine receptor alpha-1 (GLRA1) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Interacting DIG Mannitol
                    Biological Activity EC50 = 12589.25 nM (estimated based on the structural similarity with CHEMBL604608 ) [2]
                    Structural Similarity Tanimoto coefficient = 0.804878049
                    Tested Species Homo sapiens (Human)
                    UniProt ID GLRA1_HUMAN
References
1 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
2 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.